Dr Oluwole specializes in the treatment of hematological malignancies using  stem cell transplantation/ cellular therapy. He is the leader of the Vanderbilt-Ingram Cancer Center (VICC) cellular therapy research program. His primary field of research is in improving the safety profile of cellular therapy through investigator-initiated intervention trials, multi-institution sponsored therapeutic research and national consortium outcomes research. Dr Oluwole led sponsored research that showed the benefit of prophylactic corticosteroids in the treatment of CART patients and is leading efforts to safely transition CART to the outpatient setting. Dr Oluwole has published many peer-reviewed articles, reviews, book chapters, editorials and commentaries in the field of hematological malignancies, stem cell transplantation and cellular therapy. He is a reviewer for many hematological journals. He is a member of the ASTCT Committee on Cellular Therapy. He is a member of the NCCN committee for Acute Lymphoblastic Leukemia (ALL) and foundation member for the NCCN committee on the management of immunotherapy-related toxicity guidelines which includes all CARTs.

He is board certified in Internal Medicine, Hematology, and Medical Oncology